SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company's total revenue for the quarter ended June 2025 saw a slight change in the total revenue, having registered a total revenue of Rs. 23949.28 millions.A slender decline of -27.22% was recorded to Rs. 3302.26  millions from Rs. 4537.31 millions in the corresponding previous quarter.The company reported a good operating profit of 7974.94 millions compared to 6867.50 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 23949.28 23295.37 2.81 23949.28 23295.37 2.81 92264.09 78911.19 16.92
Other Income 693.35 556.48 24.60 693.35 556.48 24.60 3563.66 11680.24 -69.49
PBIDT 7974.94 6867.50 16.13 7974.94 6867.50 16.13 26005.46 24096.87 7.92
Interest 154.58 153.49 0.71 154.58 153.49 0.71 487.33 2771.10 -82.41
PBDT 4588.04 6714.01 -31.66 4588.04 6714.01 -31.66 23726.47 72029.08 -67.06
Depreciation 576.39 530.87 8.57 576.39 530.87 8.57 2186.29 2021.62 8.15
PBT 4011.65 6183.14 -35.12 4011.65 6183.14 -35.12 21540.18 70007.46 -69.23
TAX 709.39 1645.83 -56.90 709.39 1645.83 -56.90 5436.68 18334.55 -70.35
Deferred Tax 7.67 565.99 -98.64 7.67 565.99 -98.64 2275.81 7834.63 -70.95
PAT 3302.26 4537.31 -27.22 3302.26 4537.31 -27.22 16103.50 51672.91 -68.84
Equity 282.20 282.19 0.00 282.20 282.19 0.00 282.19 282.19 0.00
PBIDTM(%) 33.30 29.48 12.96 33.30 29.48 12.96 28.19 30.54 -7.70

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×